Literature DB >> 11739197

Identification and characterization of cis elements in the STAT3 gene regulating STAT3 alpha and STAT3 beta messenger RNA splicing.

H Shao1, A J Quintero, D J Tweardy.   

Abstract

Signal transducer and activator of transcription 3 (STAT3) is an oncogene and a critical regulator of multiple cell-fate decisions, including myeloid cell differentiation. Two isoforms of STAT3 have been identified: alpha (p92) and beta (p83). These differ structurally in their C-terminal transactivation domains, resulting in distinct functional activities. The cis genetic elements that regulate the ratio of alpha to beta messenger RNA (mRNA) are unknown. In this study, cloning, sequencing, and splicing analysis of the human and murine STAT3 genes revealed a highly conserved 5' donor site for generation of both alpha and beta mRNA and distinct branch-point sequences, polypyrimidine tracts, and 3' acceptor sites (ASs) for each. The beta 3' AS was found to be located 50 nucleotides downstream of the alpha 3' AS in exon 23. Two additional cryptic 3' ASs (delta and epsilon) were also identified. Thus, we identified for the first time the cis regulatory sequences responsible for generation of STAT3 alpha and STAT3 beta mRNA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11739197     DOI: 10.1182/blood.v98.13.3853

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Antitumorigenic potential of STAT3 alternative splicing modulation.

Authors:  Francesca Zammarchi; Elisa de Stanchina; Eirini Bournazou; Teerawit Supakorndej; Kathryn Martires; Elyn Riedel; Adriana D Corben; Jacqueline F Bromberg; Luca Cartegni
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-17       Impact factor: 11.205

2.  STAT3β is a tumor suppressor in acute myeloid leukemia.

Authors:  Petra Aigner; Tatsuaki Mizutani; Jaqueline Horvath; Thomas Eder; Stefan Heber; Karin Lind; Valentin Just; Herwig P Moll; Assa Yeroslaviz; Michael J M Fischer; Lukas Kenner; Balázs Győrffy; Heinz Sill; Florian Grebien; Richard Moriggl; Emilio Casanova; Dagmar Stoiber
Journal:  Blood Adv       Date:  2019-07-09

Review 3.  The Ying and Yang of STAT3 in Human Disease.

Authors:  Tiphanie P Vogel; Joshua D Milner; Megan A Cooper
Journal:  J Clin Immunol       Date:  2015-08-18       Impact factor: 8.317

Review 4.  Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.

Authors:  Uddalak Bharadwaj; Moses M Kasembeli; Prema Robinson; David J Tweardy
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

5.  Small-molecule targeting of signal transducer and activator of transcription (STAT) 3 to treat non-small cell lung cancer.

Authors:  Katherine M Lewis; Uddalak Bharadwaj; T Kris Eckols; Mikhail Kolosov; Moses M Kasembeli; Colleen Fridley; Ricardo Siller; David J Tweardy
Journal:  Lung Cancer       Date:  2015-09-15       Impact factor: 5.705

6.  Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer.

Authors:  U Bharadwaj; T K Eckols; M Kolosov; M M Kasembeli; A Adam; D Torres; X Zhang; L E Dobrolecki; W Wei; M T Lewis; B Dave; J C Chang; M D Landis; C J Creighton; M A Mancini; D J Tweardy
Journal:  Oncogene       Date:  2014-03-31       Impact factor: 9.867

7.  Monoclonal Antibodies Specific for STAT3β Reveal Its Contribution to Constitutive STAT3 Phosphorylation in Breast Cancer.

Authors:  Uddalak Bharadwaj; Moses M Kasembeli; T Kris Eckols; Mikhail Kolosov; Paul Lang; Kurt Christensen; Dean P Edwards; David J Tweardy
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

Review 8.  STAT3 and its targeting inhibitors in osteosarcoma.

Authors:  Yun Liu; Shijie Liao; Samuel Bennett; Haijun Tang; Dezhi Song; David Wood; Xinli Zhan; Jiake Xu
Journal:  Cell Prolif       Date:  2020-12-31       Impact factor: 6.831

Review 9.  STAT proteins: a kaleidoscope of canonical and non-canonical functions in immunity and cancer.

Authors:  Nagendra Awasthi; Clifford Liongue; Alister C Ward
Journal:  J Hematol Oncol       Date:  2021-11-22       Impact factor: 17.388

10.  Selective STAT3-α or -β expression reveals spliceform-specific phosphorylation kinetics, nuclear retention and distinct gene expression outcomes.

Authors:  Ivan H W Ng; Dominic C H Ng; David A Jans; Marie A Bogoyevitch
Journal:  Biochem J       Date:  2012-10-01       Impact factor: 3.857

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.